Art Cabenuva LA denied as non-formulary by Humana?

Humana's specific coverage criteria for art cabenuva la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Cabenuva (Long-Acting) as Non-Formulary

A non-formulary denial means Cabenuva is not included on Humana's covered-drug list for your specific plan, or is placed on a tier that is excluded from your benefit. This is a coverage-structure denial rather than a clinical one — Humana is not saying the drug does not work; they are saying your plan does not routinely cover it. Non-formulary denials are appealed through a formulary exception process, which all ACA-compliant and ERISA plans are required to provide.

A formulary exception appeal asks Humana to cover the drug anyway because no formulary alternative is medically appropriate for you. HIV therapy is a context where this argument is particularly strong: ART regimens are not interchangeable, and resistance patterns, tolerability, and adherence requirements make one patient's appropriate regimen potentially contraindicated or suboptimal for another.

## Your Federal Appeal Rights

• Formulary exception (internal): Under ACA §2719 and ERISA §503, plans must offer a process for requesting an exception when a formulary alternative would be medically inappropriate. This is your first step.
• Standard internal appeal: If the exception is denied, you have the right to a full internal appeal reviewed by a clinical peer not involved in the original decision.
• External review: After an adverse internal outcome, you may request external review by an independent review organization. Federal law gives you roughly four months from the original denial; your plan documents specify the exact window.
• Expedited review: Available when standard timelines would jeopardize your health; decisions typically required within 72 hours.

## What to Gather

1. List of formulary alternatives Humana identified: Request the complete list of covered HIV medications on your plan. Your prescriber must address why each formulary alternative is not medically appropriate for you. 2. Resistance testing results: Genotype or phenotype results that document susceptibility or resistance relevant to formulary alternatives. 3. Tolerability and adverse-effect history: Chart documentation of adverse effects, intolerability, or clinical failures on any formulary alternatives you have tried. 4. Adherence barrier documentation: Records showing that daily oral therapy is not clinically sustainable for you, making a long-acting injectable the medically appropriate choice. 5. Prescriber letter addressing each formulary alternative: A specific letter explaining, drug by drug, why the formulary options are medically unsuitable, with reference to your chart and the FDA-approved prescribing label for Cabenuva.

## Criteria-Mapping Structure

Build a table with one row per formulary alternative Humana listed. For each: column 1 — the alternative drug name; column 2 — why your prescriber considers it clinically inappropriate for you (resistance, prior failure, adverse history, delivery-route unsuitability); column 3 — chart source (note date or lab result). This gives the reviewer a clear, organized basis for granting the exception and documents the medical necessity of the non-formulary drug simultaneously.